## UNIVERSITY<sup>OF</sup> BIRMINGHAM University of Birmingham Research at Birmingham

# Systematic review of groin wound surgical site infection incidence after arterial intervention

Gwilym, Brenig Llwyd; Locker, Dafydd Tudor; Matthews, Emily Kate; Mazumdar, Eshan; Adamson, Georgia; Wall, Michael Lewis; Bosanquet, David Charles

DOI: 10.1111/iwj.13959

*License:* Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version Publisher's PDF, also known as Version of record

## Citation for published version (Harvard):

Gwilym, BL, Locker, DT, Matthews, EK, Mazumdar, E, Adamson, G, Wall, ML & Bosanquet, DC 2022, 'Systematic review of groin wound surgical site infection incidence after arterial intervention', *International Wound Journal*. https://doi.org/10.1111/iwj.13959

Link to publication on Research at Birmingham portal

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

## **REVIEW ARTICLE**



# Systematic review of groin wound surgical site infection incidence after arterial intervention

Brenig Llwyd Gwilym<sup>1</sup> | Dafydd Tudor Locker<sup>1</sup> | Emily Kate Matthews<sup>1</sup> | Eshan Mazumdar<sup>1</sup> | Georgia Adamson<sup>2</sup> | Michael Lewis Wall<sup>3</sup> | David Charles Bosanquet<sup>1</sup>

 <sup>1</sup>South East Wales Vascular Network, Royal Gwent Hospital, Newport, UK
<sup>2</sup>Black Country Vascular Network, Russell Hall Hospital, Dudley, UK
<sup>3</sup>University of Birmingham, Birmingham, UK

### Correspondence

Michael Lewis Wall, Black Country Vascular Network, Russell Hall Hospital, Dudley, UK. Email: michaelwall@nhs.net

## Abstract

The objectives were to determine the surgical site infection incidence (including superficial/deep) fter arterial intervention through non-infected groin incisions and identify variables associated with incidence. MEDLINE, EMBASE and CENTRAL databases were searched for randomised controlled trials and observational studies of adults undergoing arterial intervention through a groin incision and reported surgical site infection. Infection incidence was examined in subgroups, variables were subjected to meta-regression. One hundred seventeen studies reporting 65 138 groin incisions in 42 347 patients were included. Overall surgical site infection incidence per incision was 8.1% (1730/21 431): 6.3% (804/12 786) were superficial and 1.9% (241/12 863) were deep. Superficial infection incidence was higher in randomised controlled trials (15.8% [278/1762]) compared with observational studies (4.8% [526/11 024]); deep infection incidence was similar (1.7% (30/1762) and 1.9% (211/11 101) respectively). Aneurysmal pathology ( $\beta = -10.229$ , P < .001) and retrospective observational design ( $\beta = -1.118$ , P = .002) were associated with lower infection incidence. Surgical site infection being a primary outcome was associated with a higher incidence of surgical site infections ( $\beta = 3.429$ , P = .017). The three-fold higher incidence of superficial surgical site infection reported in randomised controlled trials may be because of a more robust clinical review of patients. These results should be considered when benchmarking practice and could inform future trial design.

## KEYWORDS

groin incisions, surgical site infection, vascular

## **Key Messages**

- groin wound surgical site infection (SSI) incidence varies in the literature
- the overall groin wound SSI incidence in the literature on 65 138 incisions in 42 347 patients was 8.1% (per incision)

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. *International Wound Journal* published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.

- <sup>2</sup> WILEY IWJ
- this systematic review searched the MEDLINE, EMBASE and CENTRAL databases and aimed to investigate how the variability of study design, the pathology being treated and the primary outcome may influence the reported SSI incidence after arterial intervention
- although incidence pooled from observational studies may represent the SSIs most apparent to vascular surgeons, it is likely a gross underestimation of superficial SSIs, which are more robustly captured in randomised controlled trials
- these pooled incidences can aid benchmarking and inform future trial design

## **1** | INTRODUCTION

A groin incision is commonly used in vascular surgery to expose the femoral vessels and is used for many frequently performed procedures.<sup>1,2</sup> Given the groin's proximity to the external genitalia and anal canal, skin flora and predisposition to intertrigo (particularly in obese patients)<sup>3</sup>; it is unsurprising that groin wound surgical site infections (SSIs) are commonly experienced by vascular surgery patients—a population with a high prevalence of risk factors for nosocomial infection such as diabetes and smoking.<sup>1,2</sup>

SSIs are a significant source of patient morbidity and increased health care costs.<sup>4</sup> SSIs may lead to vascular graft infection, requiring re-operation or amputation and may result in mortality.<sup>5-7</sup> 'How can we reduce surgical-site infection in vascular surgery?' was recently identified as a research priority amongst health care professionals in vascular surgery in a modified Delphi exercise<sup>8</sup>; and identifying adjuncts that prevent groin wound SSIs has been the focus of several studies.<sup>9</sup> Despite this, vascular surgery specific guidelines currently lack recommendations on strategies to monitor and prevent SSIs.<sup>10,11</sup>

The incidence of groin wound SSI following arterial intervention via a non-infected surgical field reported in the literature varies considerably,<sup>2,12-14</sup> which poses a challenge for those who wish to benchmark their own outcomes against accepted standards, and for those planning to evaluate groin wound SSI preventing interventions in adequately powered trials. The true incidence of groin wound SSI after vascular intervention is unknown; and factors that may give rise to the varying reported incidences between studies are incompletely understood.

Therefore, the primary objective of this review was to determine the reported incidence of groin wound SSI after arterial intervention through a clean surgical field. Secondary objectives were to determine the incidence of superficial and deep/organ space groin wound SSIs after arterial intervention; to determine the incidence of groin wound SSI in different study types (ie, randomised controlled trial [RCT] versus observational study) and design (ie, SSI reported as a primary or secondary outcome); and to identify variables that are associated with a higher or lower reported incidence of groin wound SSI.

## 2 | METHODS

This study was conducted in accordance with guidance in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement,<sup>15</sup> and was prospectively registered with the International prospective register of systematic reviews (PROSPERO; CRD42020185170).

## 2.1 | Data sources, search terms and inclusion/exclusion criteria

The MEDLINE, EMBASE and CENTRAL databases were searched without date restriction using the following terms: ([SSI OR SSIs OR surgical site infection OR surgical wound infection OR wound infection] AND [vascular OR arterial] AND [groin OR femoral]). The search was undertaken on 3rd June 2021.

The inclusion criteria were:

- RCTs and observational cohort studies including patients undergoing arterial intervention through a groin incision (including re-do incisions).
- Patients aged 18 and above.
- Outcome of SSI.

The exclusion criteria were:

- · Venous or cardiac procedures.
- Procedures for trauma.
- · Pre-existing groin infection (eg, infected pseudoaneurysm).
- No groin wound SSI outcome reported.
- No English version of abstract available.
- Systematic reviews.

• Preliminary results/interim results articles/abstract publication from meeting presentation (if the subsequent full results were identified)

## 2.2 | Review methods

Duplicate article removal was performed before any screening. Each of the following steps were conducted separately by two reviewers, with discrepancies referred to a third reviewer: titles and abstract screen (B.L.G., D.T.L., E.K.M., E.M., G.A.), full text screen (B.L.G., D.T.L., E.K.M., E.M., G.A.), screening of the references and related articles of the included articles (B.L.G., E.M.), data extraction (B.L.G., D.T.L., E.K.M., E.M., O.T.L., E.K.M., E.M.) and study assessment (Cochrane's risk-of-bias tool for randomised trials for RCTs and the Newcastle-Ottawa Scale for observational studies: B.L.G., D.T.L., E.K.M.).<sup>16,17</sup>

The primary outcome was the overall reported incidence of SSIs. Secondary outcomes were:

- the reported incidence of superficial and deep/organspace SSIs;
- the incidence SSI in subgroups of studies based on:
  - study design (RCT/observational, prospective/ retrospective),
  - pathology (aneurysmal/occlusive/mixed),
  - reported definition of SSI (not reported/author defined or previously published definition: Szilagyi,<sup>18</sup> Centers for Disease Control and Prevention [CDC] definition,<sup>19</sup> Southampton Wound Scale<sup>20</sup> and ASEP-SIS score),<sup>21</sup>
  - whether SSI was a primary outcome (including: single primary outcome, coprimary outcome or if part of a composite primary outcome) or not,
  - subgroups within studies (intervention and control arms of RCTs);
- the proportions of patients that were current smokers, had ischaemic heart disease, had diabetes, were obese (defined as body mass index >30 kg<sup>2</sup>), had prosthetic bypass/patch;
- the results of meta-regression analysis to identify factors associated with a higher reported incidence of SSIs;
- the reported incidences of seroma, haematoma, lymphatic leak and re-intervention to manage SSI; and surgical/medical interventions which can impact risk of SSI (longitudinal/oblique incisions, antibiotic prophylaxis, solution used for skin preparation, pre-operative skin shaving, pre-operative bathing/showering and intra-operative normothermia/glycaemia control).

Groin incisions can be unilateral or bilateral. SSI incidences were calculated on a 'per incision' basis and are reported as such unless otherwise stated. Whenever possible, the number of SSIs and/or groin incisions were derived to avoid loss of data from studies that did not explicitly report an SSI incidence 'per incision'. Studies that exclusively reported SSIs on a 'per patient' basis (including patients undergoing both unilateral and bilateral groin incision) were included, but data from these studies were only used to compare reported SSI incidence 'per patient' with the incidence 'per incision', and not used for any further analyses.

## 2.3 | Statistical analyses

Pooling of demographic variables such as male to female ratio, mean age and follow-up duration utilised the weighted mean. Data collection was designed to allow for calculation of actual incidence of SSIs (overall and subgroups). Meta-regression was used to investigate what variables impact on SSI incidence and was performed using weighted least squares regression (weighted with the inverse-variance method). Only 'per incision' data were used for regression analyses. First, univariate analyses of patient-level and study-level variables determined to be relevant by the authorship team was performed. Variables reaching P < .1 were then entered into forward stepwise multivariate analysis. Regression results are presented with 95% confidence intervals (95% CI). Statistical significance was defined was P < .05. In cases of variables with missing data being considered for inclusion in regression analyses, missing data analyses were performed. Missing data analyses consisted of examining proportion of data missing and determining whether data were missing completely at random (MCAR) with Little's MCAR test (P < .05 indicating data were not MCAR). Variables with a high proportion of data missing not at random were considered unsuitable for case-wise deletion regression and multiple imputation. Analyses were performed using Excel (Microsoft) and SPSS version 26 (IBM).

## 3 | RESULTS

After duplicate removal, the initial search produced 1160 articles (Figure 1). Following title and abstract screen, 194 articles underwent full-text review. The reference lists and related articles screen identified a further 21 articles for review. After exclusions during the full-text screen, a total of 117 articles were included. The references for all included articles are listed in Supplementary material 1.





FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Adapted from Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/)

#### 3.1 **Demographic details**

Most included studies were observational (N = 84), the remainder were RCTs (N = 33) (Table 1). Studies were published between 1978 and 2021. Overall, there were 65 138 groin incisions in 42 347 patients (60 283 incisions in 38 122 patients in observational studies; 4855 incisions in 4225 patients in RCTs). The weighted mean male to female ratio was 6.4 (6.8 in observational studies, 3.1 in RCTs), and weighted mean age was 71.4 years (71.7 for observational studies, 68.6 for RCTs). Studies were grouped according to the pathology being treated in their cohort: only occlusive disease (N = 58), only aneurysmal disease (N = 20), or aneurysmal and occlusive disease (N = 34). Five studies did not report details of their population in sufficient detail to determine which pathology category was most appropriate.

SSI was a primary, coprimary or composite primary outcome in 79 studies (28 RCTs and 51 observational). Eighty-six studies (21 431 incisions) reported SSIs using 'per incision' as a denominator, and 66 (37 565 patients) reported SSIs using 'per patient' as a denominator (35 studies reported data both 'per incision' and 'per patient'). Most studies (N = 65) did not report how SSI was defined or provided an author derived definition,

27 studies used the CDC definition,<sup>19</sup> 22 used the Szilagyi definition.<sup>18</sup> two used the Southampton wound score.<sup>20</sup> and one used the ASEPSIS score.<sup>21</sup> The definitions/ criteria are described in Supplementary material 2.

Fewer than half of all studies report categorising SSIs into superficial and deep (n = 40); of these studies, 12 did not report how SSI was defined, 6 used an author definition, 11 used the CDC definition and 11 used Silagyi. Calculated percentages for subgroups (eg, superficial and deep SSIs) reported below did not, therefore, always summate to total SSI percentages.

Reviewers determined 48.5% of RCTs to have a high risk of bias, 45.5% to have some concern for bias, and 6.1% to have a low risk of bias (Supplementary material 3). The median Newcastle-Ottawa score for observational studies was 5 and range was 1 to 7 (Supplementary material 4).

#### **Overall SSI rates** 3.2

There were 1730/21 431 SSIs, equating to an SSI incidence of 8.1% per incision (Table 2). There were more superficial SSIs (6.3%) compared with deep/organ-space SSIs (1.9%). Overall SSI incidence was lower in studies

LYM ET AL.																							N J	W	'I L	ĿE	Y–	
	SSI definition	NR	NR	NR	NR	Szilagyi	Author defined	CDC	NR	NR	Author defined	CDC	CDC	NR	Szilagyi	Author defined	NR	NR	NR	Author defined	Author defined	CDC	Szilagyi	NR	CDC	NR	Szilagyi	CDC
SSI a primary	outcome	No	NR	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	Yes	Yes	No	Yes	No	Yes	No	No	Yes
	Follow up	30 days	12 months	2.7 years	12 months	30 days	Mean 28.4 months	180 days	NR	90 days	NR	30 days	NR	NR	NR	2–62 months	Mean 28 months	Mean 39 months	Median 15 months	7 days	10 days	30 days	30 days	NR	30 days	NR	90 days	30 days
Mean	age	NR	63.6	68.5	68.3	NR	63.0	68.8	73.0	60.0	64.0	67.0	65.8	74.1	75.3	NR	75.6	NR	72.0	68.0	70.0	69.0	67.9	NR	68.0	67.8	67.6	66.0
M:F	ratio	NR	2.3	4.3	1.2	NR	1.4	2.1	11.7	2.4	1.6	2.35	1.8	4.6	7.3	NR	NR	NR	3.0	2.5	1.3	NR	5.0	NR	2.1	2.7	1.0	3.8
N groin incisions	total	822	45	138	105	422	88	NR	325	144	284	234	38	5648	176	563	76	12	322	35	167	940	09	125	568	22	553	140
N patients with groin	incision	411	43	69	95	337	44	256	195	136	284	242	38	3004	100	496	38	9	322	35	149	470	60	NR	568	11	281	140
N patients	total	484	43	69	95	337	44	256	195	136	284	242	170	4112	100	496	38	9	322	35	149	833	60	715	669	11	281	140
	Pathology <sup>e</sup>	1	2	3	2	2	2	3	1	2	2	2	2	1	1	2	3	2	2	2	3	1	7	2	2	2	2	5
	Centres <sup>b</sup>	1	2	1	1	1	1	1	1	1	1	2	1	2	1	1	1	1	2	1	1	2	1	1	1	2	1	1
Study	type <sup>a</sup>	3	2	3	3	ŝ	2	3	3	З	3	1	3	ŝ	2	2	3	3	3	1	1	ŝ	5	3	3	ю	3	б
	Location	Minneapolis, USA	Houston, USA	London, UK	Pittsburgh, USA	Cleaveland, USA	Toronto, Canada	Lebanon, USA	Jerusalem, Israel	Atlanta, USA	Durham, USA	Burlington, USA	Llantrisant, UK	Boston, USA	New York, USA	Exeter, UK	St Louis, USA	Rome, Italy	London, UK	Southampton, UK	Epsom, UK	New Haven, USA	Coimbra, Portugal	Baltimore, USA	Portland, USA	Konya, Turkey	Boston, USA	Nieuwgein, The Netherlands
	Year	2015	2017	2017	2009	2009	1990	2018	2019	2019	2016	2021	2013	2015	2000	1994	2011	2013	2020	1983	1992	2016	2014	1998	2017	2018	2020	2008
	1st Author	Aaron	Adams	Akingboye	Al-Khoury	Ambur	Ameli	Audu	Avraham	Bakshi	Bennett	Bertges	Bosanquet	Buck	Caiati	Campbell	Caputo	Cavallaro	Chaudery	Chester	Chester	Chin	Costa Almeida	Criado	Curry	Dagli	DeCarlo	Derksen

TABLE 1 Study demographic data

5

SSI definition	CDC	NR	NR	NR	Szilagyi	NR	Author defined	NR	NR	Szilagyi	NR	CDC	CDC	CDC	NR	Author defined	NR	NR	NR	CDC	Szilagyi	NR	NR	NR
SSI a primary outcome	Yes	No	Yes	No	Yes	No	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	No	Yes	No
Follow up	NR	mean 38.1 months (1-96)	NR	12 months	42 days	Mean 14 months	NR	6 weeks	5 days	30 days	2 years	90 days	3 months	3 months	Mean 10 months	Mean 29 months	22.7 months	2 weeks, 1 month, 6 months	30 days	NR	NR	27 months	NR	30 days
Mean age	NR	64.5	67.0	72.0	71.0	76.3	63.4	71.0	68.3	66.5	68.0	71.0	71.0	71.0	NR	72.0	66.0	75.0	75.0	65.5	NR	71.4	NR	73.0
M:F ratio	NR	4.0	31.0	NR	3.9	6.7	1.7	NR	1.5	0.7	0.9	2.1	2.4	1.4	NR	8.6	1.1	14.4	1.0	1.6	NR	2.3	NR	4.3
N groin incisions total	370	164	127	25	132	557	263	NR	266	217	58	1337	350	202	100	462	27	150	42	89	358	65	14	3178
N patients with groin incision	370	82	66	25	132	375	231	151	213	188	58	1039	219	178	50	231	27	77	21	69	358	58	14	1589
N patients total	370	210	66	53	132	445	231	151	213	188	117	1039	219	178	50	231	27	77	40	69	565	58	14	3122
Pathology <sup>¢</sup>	NR	2	NR	2	3	1	3	2	3	2	2	3	3	3	2	3	2	1	1	З	3	2	NR	1
Centres <sup>b</sup>	2	2	1	2	1	1	1	1	1	2	2	2	1	1	2	1	1	1	1	1	1	1	1	2
Study type <sup>a</sup>	3	ε	1	1	1	ю	ю	ю	1	1	1	7	7	1	1	ю	Э	ю	ю	5	1	ю	б	ю
Location	Durham, USA	Florence, Italy	Edinburgh, UK	Tanta, Egypt	Ulm, Germany	Miami, USA	Philadelphia, USA	Cork, Ireland	Solothurn, Switzerland	Aachen, Germany	Nantes, France	Newport, UK	Malmo, Sweden	Malmo, Sweden	Nashville, USA	Nottingham, UK	NY, USA	Jacksonville, USA	Nice, France	Boston, USA	Nashville, USA	Boston, USA	Frankfurt, Germany	Fort Gordon, USA
Year	2019	2016	1990	2019	2018	2011	2012	2018	2002	2018	2017	2020	2015	2019	1989	2003	2010	2003	2008	1993	1978	2008	2012	2016
1st Author	Dillavou	Dorigo	Dunlop	Eleissawy	Engelhardt	Etezadi	Fischer	Fleming	Giovannacci	Gombert	Goueffic	Gwilym	Hasselmann	Hasselmann	Healy	Hinchliffe	Hines	Jackson Slappy	Jean- Baptiste	Josephs	Kaiser	Kang	Karl	Kauvar

1742481x, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ivj.13959 by Test, Wiley Online Library on [20/02/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

00     111     111	N N   Study Study   éar Location   type <sup>a</sup> Centres <sup>b</sup> Pathology <sup>c</sup> total	Study Study type <sup>4</sup> Centres <sup>b</sup> Pathology <sup>c</sup> total	N patients Centres <sup>b</sup> Pathology <sup>c</sup> total	N patients Pathology <sup>c</sup> total	N patients total		N patients with groin incision	N groin incisions total	M:F ratio	Mean age	Follow up	SSI a primary outcome	SSI definition
90     90     91     92     700     NR     NR     NR     NR     NR     NR     Szilagyi       106     106     106     106     106     107     80     NR     NR     NR       112     113     117     117     64.3     30 days     Yes     CDC       120     121     117     117     64.3     30 days     Yes     CDC       121     121     117     127     64.3     30 days     Yes     CDC       122     141     117     157     70     Mean 15.2 months     No     NR       123     161     707     30 days     Yes     CDC       164     173     157     30 days     Yes     CDC       164     164     2799     40     Yes     CDC       164     164     30 days     Yes     CDC       164     164     170     170     No     NR       164     164     206	1996 Boston, USA 2 2 2 1994 Allentown, USA 3 1 3	2 2 2 3 3 1 3 2	1 2	m 7		150 1637	50 1637	NR	I.6 NR	71.5 NR	NR NR	Yes Yes	Szilagyi NR
604     NR     NR     NR     NR     NR     NR     NR       106     106     106     106     106     107     703     703     703     703       112     117     117     117     117     117     703     703     703       123     124     123     106     703     7043     703     703       123     124     127     126     703     7043     703     703       123     126     703     704     704     703     703     703       124     121     127     123     663     7043     703     703       104     104     773     720     720     7043     703     703       104     104     773     663     7043     703     703     703       105     106     773     663     7043     703     703     703       1064     1064     773     723     663 </td <td>2015 Zwolle, 2 1 2 Netherlands</td> <td>2 1 2</td> <td>1 2</td> <td>5</td> <td></td> <td>06</td> <td>06</td> <td>06</td> <td>2.5</td> <td>70.0</td> <td>NR</td> <td>Yes</td> <td>Szilagyi</td>	2015 Zwolle, 2 1 2 Netherlands	2 1 2	1 2	5		06	06	06	2.5	70.0	NR	Yes	Szilagyi
106     106     106     106     106     106     106     106     106     106     106     106     107     100     108 <td>2013 Texas, USA 2 1 2</td> <td>2 1 2</td> <td>1 2</td> <td>2</td> <td></td> <td>604</td> <td>604</td> <td>NR</td> <td>NR</td> <td>NR</td> <td>NR</td> <td>Yes</td> <td>NR</td>	2013 Texas, USA 2 1 2	2 1 2	1 2	2		604	604	NR	NR	NR	NR	Yes	NR
12     147     1.7     64.3     30 days     Yes     Szilagyi       30     30     33     90     760     Mem 15.2 months     No     NR       229     233     1.6     70.7     3 months     Yes     CDC       181     181     187     16.4     200     3 months     Yes     CDC       182     141     177     15.7     72.0     30 days     Yes     CDC       182     164     17     15.7     72.0     30 days     No     NR       182     102     102     15.7     72.0     30 days     No     NR       103     103     103     63.0     Median 30 months     No     NR       104     104     279     44.0     70.0     Median 30 months     No     NR       105     102     103     63.0     63.0     30 days     No     NR       104     164     112.5     64.0     NR     No     NR	2014 Milwaukee, USA 3 1 3	3 1 3	1 3	3		106	106	106	1.6	62.0	30 days	Yes	CDC
30     30     70     Ken     Men     NR       229     233     1.6     7.7     3 months     Yes     CDC       11     1     81     NR     69.4     2 weeks/healed     Yes     CDC       182     141     177     15.7     72.0     30 days     No     NR       182     141     177     15.7     72.0     30 days     No     NR       182     102     102     3.3     68.5     90 days     Yes     CDC       1040     1604     160     7.2     Median 30 months     Yes     CDC       105     102     3.2     63.0     Median 30 months     Yes     CDC       106     103     127     3.0     30 days     Yes     CDC       106     115     2.0     54.0     30 days     Yes     NR       107     112.5     65.0     30 days     Yes     NR     NR       108     112.6     112.5     65.0	2018 Philadelphia, USA 1 1 3	1 1 3	1 3	3		122	122	147	1.7	64.3	30 days	Yes	Szilagyi
229     233     1.6     70.7     3 months     Yes     CDC       11     11     11     11     14     17     5.1     30 days     Yes     ASEPSISscore       182     141     177     15.7     72.0     30 days     Yes     CDC       182     102     102     3.3     68.5     90 days     Yes     CDC       104     104     2799     40     75.2     Mean 36 months     Yes     CDC       108     102     3.2     68.0     30 days     No     NR       108     103     103     68.0     30 days     No     NR       109     115     6.0     30 days     Yes     NR     NR       104     115     6.10     30 days     Yes     NR     NR       104     115     6.10     30 days     Yes     NR     NR       104     114     112     6.10     30 days     Yes     NR       104	2006 Varese, Italy 2 1 1	2 1 1	1 1	1		30	30	33	9.0	76.0	Mean 15.2 months	No	NR
51     51     81     NR     69.4     2 weeks/ healed     Yes     ASEPSIS score       182     141     177     15.7     7.0     30 days     No     N       102     102     102     3.3     68.5     90 days     Yes     CDC       104     1604     2799     4.0     75.2     Mean 36 months     Yes     CDC       108     108     127     3.2     63.0     Median 30 months     Yes     CDC       108     103     2.0     68.0     30 days     No     NR       2040     90     115     2.0     64.0     Ne     NR       45     115     6.0     30 days     Yes     NR     NR       45     112     6.1     NR     Yes     NR     NR       45     64     NR     Yes     NR     NR       45     112     650     30 days     Yes     NR       46     114     112     650     3	2018 Breda, Netherlands 3 1 2	3 1 2	1 2	2		229	229	233	1.6	70.7	3 months	Yes	CDC
182     141     177     15.7     72.0     30 days     No     NR       102     102     102     3.3     68.5     90 days     Yes     CDC       104     1604     2799     4.0     75.2     Mean 36 months     Yes     CDC       108     108     127     3.2     63.0     Median 30 months     No     NR       206     93     2.0     63.0     30 days     No     NR       206     91     115     2.0     63.4     NR     No     NR       454     115     2.0     54.0     30 days     Yes     NR       454     454     112.5     65.0     30 days     Yes     NR       456     456     7.16     Mean 14 months     No     NR     NR       456     112.5     65.0     30 days     Yes     NR       451     114     114     117     No     NR     NR       450     112.6     57.0	2011 Ontario, Canada 1 1 3	1 1 3	1 3	3		51	51	81	NR	69.4	2 weeks/ healed	Yes	ASEPSIS score
102     102     3.3     6.8.5     90 days     Yes     CDC       1604     1604     2799     4.0     75.2     Mean 36 months     Yes     CDC       108     103     127     3.2     63.0     Median 30 months     No     NR       206     93     93     54.0     54.0     No     NR       206     94     115     54.0     54.0     30 days     Yes     NR       454     155     63.4     NR     Yes     NR     NR       454     112.5     65.0     30 days     Yes     NR     NR       454     114     117     112.5     65.0     30 days     Yes     NR       456     0.1     65.0     30 days     Yes     NR     NR       450     114     173     1.1     65.0     14 days     Yes     NR       451     114     173     1.1     65.0     NR     Yes     NR       450	2014 California, USA 3 2 1	3 2 1	2 1	1		182	141	177	15.7	72.0	30 days	No	NR
1604     1604     2790     4.0     75.2     Mean 36 months     Yes     CDC       108     127     3.2     63.0     Median 30 months     No     NR       206     93     2.0     68.0     30 days     No     NR       206     90     115     2.0     68.0     30 days     Yes     NR       454     454     112.5     50.0     30 days     Yes     NR       454     454     112.5     65.0     30 days     Yes     NR       456     454     112.5     65.0     30 days     Yes     NR       46     46     8.2     71.6     Mean 14 months     No     NR       41     114     173     1.1     65.0     30 days     Yes     NR       410     173     1.1     67.0     NR     Yes     NR       4114     114     173     1.6     71.6     Yes     NR       425     81     NR     Yes	2017 Ontario, Canada 1 1 2	1 1 2	1 2	2		102	102	102	3.3	68.5	90 days	Yes	CDC
108     107     3.2     63.0     Median 30 months     No     NR       206     93     93     54.0     80.0     No     NR       90     91     15     2.0     68.0     30 days     Yes     Stalagyi       64     64     115     6.0     30 days     Yes     NR       64     64     7.0     6.1     NR     Yes     NR       64     64     8.2     71.6     Mean 14 months     No     NR       104     114     173     1.7     67.0     30 days     Yes     NR       114     114     173     1.7     67.0     30 days     Yes     NR       114     114     173     1.7     67.0     Yes     NR       114     114     173     1.7     67.0     Yes     NR       114     114     173     1.7     67.0     Yes     NR       115     67.0     NR     Yes     Yes <td< td=""><td>2015 Tokyo, Japan 3 1 1</td><td>3 1 1</td><td>1 1</td><td>1</td><td></td><td>1604</td><td>1604</td><td>2799</td><td>4.0</td><td>75.2</td><td>Mean 36 months</td><td>Yes</td><td>CDC</td></td<>	2015 Tokyo, Japan 3 1 1	3 1 1	1 1	1		1604	1604	2799	4.0	75.2	Mean 36 months	Yes	CDC
206     93     93     2.0     68.0     30 days     No     NR       90     90     115     2.0     54.0     30 days     Yes     Szlagyi       64     64     64     3.6     5.4     NR     Yes     NR       454     454     112.5     65.0     30 days     Yes     NR       46     45     71.6     Mean 14 months     No     NR       30     30     30     30 days     Yes     NR       414     114     173     1.1     65.0     30 days     Yes     NR       114     114     173     1.1     67.0     14 days     Yes     NR       250     247     247     1.6     67.8     NR     Yes     NR       661     67.0     70.0     NR     Yes     NR     NR       89     97     1.6     70.8     NR     Yes     NR       161     161     870     NR     Yes	2016 Amiens, France 3 1 2	3 1 2	1 2	2		108	108	127	3.2	63.0	Median 30 months	No	NR
90     90     115     2.0     54.0     30 days     Yes     Salagyi       64     64     3.6     63.4     NR     Yes     NR       454     454     112.5     65.0     30 days     Yes     NR       454     454     112.5     65.0     30 days     Yes     NR       456     46     8.2     71.6     Mean 14 months     No     NR       30     30     30     1.1     65.0     30 days     Yes     NR       114     114     173     1.7     67.0     14 days     Yes     NR       250     247     1.6     71.0     NR     Yes     NR       250     247     1.6     71.0     NR     Yes     NR       251     2.0     70.0     NR     Yes     NR       256     2.9     77.0     70 days     Yes     NR       256     2.9     77.0     70 days     Yes     Salagyi	2018 Hamburg, Germany 3 1 1	y 3 1 1	1 1	1		206	93	93	2.0	68.0	30 days	No	NR
64     64     63.4     NR     Yes     NR       454     454     112.5     65.0     30 days     Yes     NR       46     46     8.2     71.6     Mean 14 months     No     NR       30     30     30     11     65.0     30 days     Yes     NR       114     114     173     1.7     67.0     14 days     Yes     NR       250     247     247     1.6     67.8     NR     Yes     NR       661     873     1.7     67.0     14 days     Yes     NR       652     247     247     1.6     NR     Yes     NR       661     873     2.00     NR     Yes     NR       756     330     2.9     77.0     30 days     Yes     Stalagyi       16     16     16.0     65.0     Mean 28 months     No     NR       16     16     16.0     30 days     Yes     Stalagyi	2013 Shreveport, USA 3 1 3	3 1 3	1 3	ю		90	06	115	2.0	54.0	30 days	Yes	Szilagyi
454     454     112.5     65.0     30 days     Yes     NR       46     46     8.2     71.6     Mean 14 months     No     NR       30     30     30     1.1     65.0     30 days     Yes     NR       114     114     173     1.7     67.0     14 days     Yes     NR       250     247     1.6     67.0     14 days     Yes     NR       661     873     1.7     67.0     14 days     Yes     NR       661     873     2.0     70.0     NR     Yes     NR       89     97     NR     64.0     Nea 28 months     No     NR       16     16     70.0     30 days     Yes     Scilagin       16     16     65.0     30 days     Yes     Scilagin       16     16     70.0     30 days     Yes     Scilagin	1993 Scarborough, UK 1 1 2	1 1 2	1 2	2		64	64	64	3.6	63.4	NR	Yes	NR
46     46     8.2     71.6     Mean 14 months     No     NR       30     30     30     1.1     65.0     30 days     Yes     NR       114     113     1.7     67.0     14 days     Yes     NR       250     247     247     1.6     67.0     14 days     Yes     NR       661     873     2.0     70.0     NR     Yes     NR       691     873     2.0     70.0     NR     Yes     NR       16     97     NR     64.0     Mean 28 months     No     NR       16     16     16.0     65.0     30 days     Yes     Szilagyi       16     16     16.0     65.0     Mean 28 months     No     Author defined       16     16     16.0     65.0     Mean 28 months     No     Mithor defined	2013 Houston, USA 3 1 2	3 1 2	1 2	2		454	454	454	112.5	65.0	30 days	Yes	NR
30     30     1.1     65.0     30 days     Yes     NR       114     114     173     1.7     67.0     14 days     Yes     NR       250     247     1.6     67.0     14 days     Yes     NR       250     247     1.6     67.0     14 days     Yes     NR       661     873     2.0     70.0     NR     Yes     NR       89     97     NR     64.0     Mean 28 months     No     NR       256     256     330     2.9     77.0     30 days     Yes     Szilagyi       16     16     16.0     65.0     Mean 28 months     No     Nathor defined       16     16     16.0     65.0     Mean 28 months     No     Muthor defined       16     16     65.0     Mean 28 months     No     Muthor defined	1996 California, USA 2 2 1	2 2 1	2 1	1		46	46	46	8.2	71.6	Mean 14 months	No	NR
114     113     1.7     67.0     14 days     Yes     NR       250     247     1.6     67.8     NR     Yes     NR       661     873     2.0     70.0     NR     Yes     NR       89     97     NR     64.0     Mean 28 months     No     NR       256     330     2.9     77.0     30 days     Yes     Szilagyi       16     16     16.0     65.0     Mean 28 months     No     Author defined       16     16     16.0     65.0     Mean 28 months     No     Author defined       16     16     16.0     65.0     Mean 28 months     No     Author defined       16     16     16.0     65.0     Mean 28 months     No     Author defined       16     16     16.0     65.0     Mean 28 months     No     Author defined	2018 Virginia, USA 1 1 NR	1 1 NR	1 NR	NR		30	30	30	1.1	65.0	30 days	Yes	NR
250     247     1.6     67.8     NR     Yes     NR       661     671     873     2.0     70.0     NR     Yes     NR       89     97     NR     64.0     Mean 28 months     No     Ne       256     256     330     2.9     77.0     30 days     Yes     Szilagyi       16     16     16.0     65.0     Mean 28 months     No     Ne       16     16     16.0     65.0     Mean 28 months     No     Nethor defined       16     16     16.0     65.0     Mean 28 months     No     Author defined       16     16     16.0     65.0     Mean 28 months     No     Author defined	1995 Dublin, Ireland 1 1 2	1 1 2	1 2	2		114	114	173	1.7	67.0	14 days	Yes	NR
661     673     2.0     70.0     NR     Yes     NR       89     97     NR     64.0     Mean 28 months     No     NR       256     330     2.9     77.0     30 days     Yes     Szilagyi       16     16     16     65.0     Mean 28 months     No     Author defined       13     30 days     28     80     80     80     80     80	1999 Philadelphia, USA 3 2 3	3 2 3	2 3	3		250	247	247	1.6	67.8	NR	Yes	NR
89     97     NR     64.0     Mean 28 months     No     NR       256     256     330     2.9     77.0     30 days     Yes     Szilagyi       16     16     16     65.0     Mean 28 months     No     Author defined       17     90 days     30 days     30 days     30 days     30 days	(991 Bristol, UK 3 1 3	3 1 3	1 3	3		661	661	873	2.0	70.0	NR	Yes	NR
256     256     330     2.9     77.0     30 days     Yes     Szilagyi       16     16     16.0     65.0     Mean 28 months     No     Author defined (within 30 days)	2017 Virginia, USA 3 1 2	3 1 2	1 2	2		89	89	97	NR	64.0	Mean 28 months	No	NR
16     16     16.0     65.0     Mean 28 months     No     Author defined       (within     30 days)     30 days)     30 days)	2019 Turku, Finland 3 1 3	3 1 3	1 3	3		256	256	330	2.9	77.0	30 days	Yes	Szilagyi
	1993 California, USA 3 1 2	3 1 2	1 2	7		16	16	16	16.0	65.0	Mean 28 months	No	Author defined (within 30 days)

	SSI definition	CDC	CDC	Szilagyi	CDC	NR	Author defined	NR	CDC	NR	Szilagyi	Szilagyi	Szilagyi	Author defined	Szilagyi	Szilagyi	NR	Szilagyi	NR	NR	NR	NR	CDC	NR
	SSI a primary outcome	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes
	Follow up	NR	30 days	Mean 219 days	90 days	90 days	6 months	30 days	1 year	Mean 3.54 years	28 days	30 days	6 weeks	NR	1 year	3 years (30 days for SSI)	30 days	30 days	4 months	NR	30 days	Median 21 (30 days for SSI)	30 days	NR
	Mean age	66.0	67.6	65.0	68.0	65.0	61.6	NR	NR	50.2	59.8	68.8	68.0	65.5	73.5	NR	72.0	55.9	NR	70.0	NR	62.0	68.7	NR
	M:F ratio	3.4	2.6	1.3	NR	2.1	4.5	NR	NR	0.5	2.7	2.6	1.7	n/a	1.6	NR	NR	4.4	NR	2.3	11.5	2.2	1.6	NR
	N groin incisions total	310	124	156	NR	NR	240	8	NR	248	231	129	198	123	163	298	631	168	63	60	193	155	1513	45
	N patients with groin incision	310	62	150	221	67	120	7	451	162	205	100	171	114	NR	149	580	124	49	30	100	155	1513	45
	N patients total	756	500	150	221	169	120	7	451	162	205	100	171	117	189	289	580	124	49	30	100	155	1513	45
	a <sup>b</sup> Pathology <sup>c</sup>	ω	3	2	2	3	2	2	2	2	2	3	£	7	£	ω	2	ŝ	3	1	1	7	2	2
	Centres	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	2	1
	Study type <sup>a</sup>	б	1	3	3	1	2	ю	ю	3	1	1	1	ю	З	3	1	7	1	ю	2	ю	3	2
~	Location	Hannover, Germany	Houston, USA	Miami, USA	New York, USA	Charleston, USA	Belgrade, Serbia	Michigan, USA	Ohio, USA	Minnesota, USA	Dublin, Ireland	Siegen, Germany	The Hague, Netherlands	Milwaukee, USA	Lund, Sweden	Poitiers, France	Malmo, Sweden	Durban, South Africa	New York, USA	Wilmington, USA	Thessaloniki, Greece	Budapest, Hungary	New York, USA	Tel-Aviv, Israel
,	Year	2012	2014	2017	2018	2010	2014	2017	2012	2011	1980	2017	2009	1992	2019	2006	1995	1988	2016	2013	2008	2011	2014	1980
	1st Author	Ott	Ozaki	Parikh	Parizh	Patrick	Pejkic	Pesonen	Peterson	Piazza	Pitt	Pleger	Ploeg	Reifsnyder	Rezk	Ricco	Risberg	Robbs	Sabat	Santin	Saratzis	Simó	Siracuse	Stavorovsky

<sup>8</sup> \_\_\_\_WILEY \_\_\_\_\_

GWILYM ET AL.

1742481x, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ivj.13959 by Test, Wiley Online Library on [20/02/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

1st Author	Year	Location	Study type <sup>a</sup>	Centres <sup>b</sup>	Pathology <sup>e</sup>	N patients total	N patients with groin incision	N groin incisions total	M:F ratio	Mean age	Follow up	SSI a primary outcome	SSI definition
Swinnen	2010	Westmead, Australia		7	NR	88	88	116	2.5	NR	28 days	Yes	CDC
Teixeira	2015	Porto, Portugal	3	1	3	279	279	358	3.9	0.69	30 days	Yes	CDC
Torsello	2003	Munster, Germany	1	1	1	30	15	NR	NR	71.0	NR	No	NR
Trinidad	2019	Tuscon, USA	ю	2	1	14 868	14 868	29 736	4.3	73.6	30 days	Yes	CDC
Turtiainen	2011	Joensuu, Finland	1	2	2	274	103	103	1.5	72.5	30 days	Yes	CDC
Uhl	2018	Regensburg, Germany	ю	1	2	108	108	115	1.4	65.0	30 days	No	NR
Uhl	2020	Regensburg, Germany	б	1	7	20	20	23	1.2	59.0	30 days	No	NR
van der Slegt	2014	Breda, Netherlands	3	1	7	255	255	292	2.1	71.9	90 days	Yes	CDC
van Himbeeck	1992	Nijmegen, Netherlands	7	1	7	603	NR	452	NR	NR	Median 45 months	Yes	Szilagyi
Vierhout	2014	Assen, Netherlands	1	1	2	47	47	47	1.5	NR	6 weeks	Yes	Southampton Wound Scale
Vierhout	2018	Assen, Netherlands	1	7	1	137	137	137	9.0	72.0	2 weeks	Yes	Southampton Wound Scale
Walker	1998	Nottingham, UK	2	1	3	136	136	272	NR	NR	Median 7 months	Yes	Author defined
Watson	2004	Columbus, USA	2	1	1	134	134	278	8.5	71.6	30 days	Yes	Author defined
Wengrovitz	1990	Hershey, USA	3	1	2	163	163	163	2.5	NR	NR	Yes	Szilagyi
Worning	1986	Copenhagen, Denmark	1	1	б	155	NR	164	NR	NR	NR	Yes	Szilagyi
Wubbeke	2020	Maastricht, Netherlands	1	5	ε	288	288	288	2.5	69.5	6 weeks	Yes	CDC
Youssef	2005	London, UK	1	1	2	73	73	106	1.2	72.0	5 days	No	Author defined
Zamani	2018	Houston, USA	3	1	2	338	NR	317	165.7	65.2	30 days	Yes	CDC
Abbreviations: Cl <sup>a</sup> 1: Randomised C <sup>b</sup> 1: Single; 2: Mult <sup>c</sup> 1: Aneurysmal; 2	DC, Cente controlled iple. : Occlusiv	rs for Disease Control an Trial; 2: Prospective obse e; 3: Aneurysmal and occ	d preventio rvational; : lusive.	n; NR, not repc 3: Retrospective	orted; SSI, surgic observational.	al site infection	ć						

that only included patients undergoing intervention for aneurysmal disease (1.5%) compared with studies that only included patients undergoing intervention for occlusive disease (9.9%) or studies that included patients undergoing both aneurysmal and occlusive disease (11.0%).

The incidence of SSIs was higher in studies that used a previously published definition for SSI diagnosis (10.7%) compared with studies that either report an author definition or do not report how SSI was defined (6.0%). Incidence was almost double when observing studies where SSI was a primary outcome (9.1%) compared with studies where SSI was not a primary outcome (5.2%).

SSI incidence was reported on a 'per patient' basis for 37 565 patients, of which 1902 patients developed a groin SSI (giving an SSI incidence of 5.1% 'per patient'). Within this cohort, the ratio of groin incisions to patients with a groin incision was 1.6. An estimated SSI rate per incision would, therefore, be 5.1% multiplied by 1.6, which equals 8.16%. This is almost exactly the same rate captured by the studies reporting SSIs per incision (8.1%).

## 3.3 | Randomised controlled trials

The overall incidence of SSIs in RCTs was 11.9% (477/4007). Superficial SSIs (15.8%) occurred more frequently than deep SSIs (1.7%). The control arms of RCTs experienced a higher incidence of SSIs (16.0%) than the intervention arms (9.1%). This was a consistent finding when looking at subgroups of studies based on pathology and SSI definition; but was more prominent in studies where SSI was a primary outcome (Table 2).

SSI incidence was lower in studies that only included patients undergoing intervention for aneurysmal disease (1.5%) compared with studies that only included patients undergoing intervention for occlusive disease (10.2%) or studies that included patients undergoing both aneurysmal and occlusive disease (13.1%). Similarly, SSI incidence was higher in studies where SSI was a primary outcome (12.7%) compared with studies where SSI was not a primary outcome (5.7%). Overall and superficial SSI incidence was lower when the authors did not report an existing definition for SSI compared with studies where SSI was defined according to an existing definition/ grading system (overall SSI incidence: 9.8% and 12.9% respectively, and superficial SSI incidence: 11.1% and 18.0% respectively), but deep SSI incidence was lower (2.6% and 1.3% respectively). Several RCTs, 78.8% (26/33) evaluated an intervention aimed at reducing SSIs in groin wounds. Closed incision negative pressure wound therapy (ciNPWT) was evaluated in 7 (26.9%) studies,

intravenous antibiotics (versus oral or other intravenous preparations) was evaluated in 3 (11.5%) studies, local/ topical antibiotics placed into the wound before closure was evaluated in 2 (8.0%) studies. The following interventions were evaluated in single studies: platelet-rich plasma, twice-daily skin preparation for 2 days preoperatively versus standard skin prep, subcuticular suture versus transcutaneous, silver alginate dressing, lateral dissection, supplemental oxygen, and cryanocrylate skin sealant.

## 3.4 | Observational

Overall SSI incidence in observational studies was 7.2% (1253/17 424). Superficial SSIs (4.8%) were more frequent than deep SSIs (1.9%). The incidence of SSIs was lower in studies that only included patients undergoing intervention for aneurysmal disease (1.5%) compared with studies that only included patients undergoing intervention for occlusive disease (9.8%) or studies that included patients undergoing both aneurysmal and occlusive disease (10.0%). Studies that used an existing SSI definition reported a higher SSI incidence (9.8%) compared with studies that did not report an SSI definition or used an author definition (5.6%). Studies that had SSI as a primary outcome, when compared with studies where SSI was not a primary outcome, had a higher overall SSI incidence (8.1% and 5.1% respectively) but lower incidence of superficial (4.6% and 5.7% respectively) and deep SSIs (2.0% and 1.5% respectively).

## 3.5 | Meta-regression

Meta-regression results are presented in Table 3. Univariate analysis identified the following variables as significantly associated with a lower reported SSI incidence: increasing mean age, only aneurysmal pathology (relative to only occlusive), prospective observational design (relative to RCT), retrospective observational design (relative to RCT), CDC definition (relative to no reported definition), SSI being a primary outcome, and more recent year of publication. The variables identified as significantly associated with a higher incidence of SSIs in univariate analysis were: increasing male to female ratio and Szilagyi definition (relative to no reported definition).

Multivariate analysis identified aneurysmal pathology (reference: occlusive,  $\beta = -10.229$ , 95% CI -12.585 to -7.873, P < .001) and retrospective observational study design (reference: RCT,  $\beta = -1.118$ , 95% CI -1.800 to -0.436, P = .002) as independent predictors of a lower reported SSI incidence, whereas SSI being a primary

WILYM ET AL.					
ABLE 2 Incide	nces of surgical site infection	(number of infections	/number of incisions [	%])	
Variable	Observational study and RCT	Observational study	RCT both arms	RCT intervention arm	RCT control arm
All studies					
SSI	1730/21 431 (8.1)	1253/17 424 (7.2)	477/4007 (11.9)	168/1838 (9.1)	289/1807 (16.0)
Superficial SSI	804/12 786 (6.3)	526/11 024 (4.8)	278/1762 (15.8)	115/849 (13.6)	166/915 (18.1)
Deep SSI	241/12 863 (1.9)	211/11 101 (1.9)	30/1762 (1.7)	11/849 (1.3)	20/915 (2.2)
Studies that include	e aneurysmal pathology only				
SSI	88/5888 (1.5)	86/5751 (1.5)	2/137 (1.5)	0/73 (0)	2/73 (3.1)
Superficial SSI	20/3638 (0.6)	20/3638 (0.6)	NR	NR	NR
Deep SSI	7/3638 (0.2)	7/3638 (0.2)	NR	NR	NR
Studies that include	e occlusive pathology only				
SSI	751/7600 (9.9)	621/6322 (9.8)	130/1278 (10.2)	41/561 (7.3)	73/561 (13.9)
Superficial SSI	304/3894 (10.0)	253/3360 (7.5)	51/534 (9.6)	26 (10.5)	28/213 (9.5)
Deep SSI	86/3971 (2.2)	79/3437 (2.3)	7/534 (1.3)	5/247 (2.0)	3/296 (1.0)
Studies that include	e aneurysmal and occlusive p	athology			
SSI	803/7300 (11.0)	500/4981 (10.0)	303/2319 (13.1)	108/1068 (10.1)	191/1080 (17.7)
Superficial SSI	475/5224 (9.1)	253/4026 (6.3)	222/1198 (18.5)	85/586 (14.5)	137/605 (22.7)
Deep SSI	147/5224 (2.8)	125/4026 (3.1)	22/1198 (1.8)	5/586 (0.9)	17/605 (2.8)
Studies that use the	e author's definition of SSI or	not reported			

	Superficial SSI	20/3638 (0.6)	20/3638 (0.6)	NR	NR	NR
	Deep SSI	7/3638 (0.2)	7/3638 (0.2)	NR	NR	NR
St	udies that include	occlusive pathology only				
	SSI	751/7600 (9.9)	621/6322 (9.8)	130/1278 (10.2)	41/561 (7.3)	73/561 (13.9)
	Superficial SSI	304/3894 (10.0)	253/3360 (7.5)	51/534 (9.6)	26 (10.5)	28/213 (9.5)
	Deep SSI	86/3971 (2.2)	79/3437 (2.3)	7/534 (1.3)	5/247 (2.0)	3/296 (1.0)
St	udies that include	aneurysmal and occlusive pat	hology			
	SSI	803/7300 (11.0)	500/4981 (10.0)	303/2319 (13.1)	108/1068 (10.1)	191/1080 (17.7)
	Superficial SSI	475/5224 (9.1)	253/4026 (6.3)	222/1198 (18.5)	85/586 (14.5)	137/605 (22.7)
	Deep SSI	147/5224 (2.8)	125/4026 (3.1)	22/1198 (1.8)	5/586 (0.9)	17/605 (2.8)
St	udies that use the a	author's definition of SSI or ne	ot reported			
	SSI	725/12 004 (6.0)	595/10 681 (5.6)	130/1323 (9.8)	36/513 (7.0)	88/614 (14.3)
	Superficial SSI	288/7870 (3.7)	224/7294 (3.1)	64/576 (11.1)	15/215 (7.0)	47/329 (14.3)
	Deep SSI	123/7870 (1.6)	108/7294 (1.5)	15/576 (2.6)	4/215 (1.9)	11/329 (3.3)
St	udies that use a for	rmal definition of SSI				
	SSI	1005/9427 (10.7)	658/6743 (9.8)	347/2684 (12.9)	132/1325 (10.0)	201/1193 (16.9)
	Superficial SSI	516/4916 (10.5)	302/3730 (8.1)	214/1186 (18.0)	100/634 (15.8)	119/586 (20.3)
	Deep SSI	118/4993 (2.4)	103/3807 (2.7)	15/1186 (1.3)	7/634 (1.1)	9/586 (1.5)
St	udies that include	SSI as a primary outcome				
	SSI	1430/15 638 (9.1)	979/12 086 (8.1)	451/3552 (12.7)	164/1706 (9.6)	283/1673 (16.9)
	Superficial SSI	671/10 283 (6.5)	401/8812 (4.6)	270/1471 (18.4)	111/717 (15.5)	164/781 (21.0)
	Deep SSI	205/10 360 (2.0)	179/8889 (2.0)	26/1471 (1.8)	11/717 (1.5)	16/781 (2.1)
St	udies where SSI no	ot a primary outcome				
	SSI	300/5793 (5.2)	274/5338 (5.1)	26/455 (5.7)	4/132 (3.0)	6/134 (4.5)
	Superficial SSI	133/2503 (6.8)	125/2212 (5.7)	8/291 (2.8)	4/132 (3.0)	2/134 (1.5)
	Deep SSI	36/2503 (1.4)	32/2212 (1.5)	4/291 (1.4)	0/132 (0)	4/134 (3.0)

Abbreviations: RCT, randomised controlled trials; SSI, surgical site infection.

outcome ( $\beta$  = 3.429, 95% CI 0.645 to 6.212, P = .017) was an independent predictor of a higher reported SSI incidence.

#### Comorbidities and practices that 3.6 may impact SSI incidence

Information regarding comorbidities and surgical practice relevant to SSI prevention was generally infrequently, and

heterogeneously, reported (Supplementary material 5). Little's MCAR test *P*-value = .015. Owing to the high proportion of missing data and that data were not missing completely at random, they could not be included in metaregression using case-wise deletion and were not appropriate for multiple imputation.

The median (interquartile range [IQR]) proportion of patients that: were current smokers = 50.0% (33.6%-70.0%), had ischaemic heart disease = 41.0% (27.1%-48.8%), had diabetes = 28.6% (17.7%-37.8%), had a body

Variable	β	95% CI	P
Univariate analysis			
Male:Female ratio	.111	-0.020 to 0.243	.095*
Mean age	-1.177	−1.471 to −0.883	<.001*
Pathology: occlusive	Reference		
Pathology: aneurysmal	-8.930	-11.710 to -6.149	<.001*
Pathology: aneurysmal and occlusive	3.395	-0.880 to 7.669	.118
Randomised controlled trial	Reference		
Prospective observational	-6.001	-13.089 to 1.087	.096*
Retrospective observational	-12.025	-16.313 to -7.738	<.001*
SSI definition: Not reported	Reference		
SSI definition: Author defined	2.846	-5.176 to 10.868	.482
SSI definition: CDC	-6.191	-9.949 to -2.433	.002*
SSI definition: Szilagyi	6.861	0.349 to 13.373	.039*
SSI definition: ASESPSIS	7.072	-16.440 to 30.585	.551
SSI definition: Southampton wound scale	-2.670	-19.431 to 14.092	.752
SSI not a primary outcome	Reference		
SSI a primary outcome	-5.360	-10.241 to -0.451	.033*
Year of publication	234	-0.438 to -0.030	.025*
Multivariate analysis			
Pathology: occlusive	Reference		
Pathology: aneurysmal	-10.229	-12.585 to -7.873	<.001
RCT	Reference		
Retrospective observational	-1.118	-1.800 to -0.436	.002
SSI not a primary outcome	Reference		
SSI a primary outcome	3.429	0.645 to 6.212	.017

**TABLE 3**Results of meta-regression analyses to predict anincrease in the reported Surgical SiteInfection incidence

Abbreviations: CDC, Centers for Disease Control and Prevention; RCT, randomised controlled trial; SSI, surgical site infection; 95% CI, 95% confidence interval.

*Note*: \* indicates significance at P < .1 level.

mass index of over 30 kg/m<sup>2</sup> = 32.0% (21.0%-40.9%), had a prosthetic bypass/patch = 25.4% (0.0%-55.4%). The number of studies with missing data for smoking status, ischaemic heart disease, diabetes, body mass index, and bypass/patch material were: 58 (49.6%), 67 (57.3%), 37 (31.6%), 94 (80.3%), 55 (47.0%).

Incision type was only longitudinal in 21 studies (18.0%), only oblique in 9 studies (7.7%), either longitudinal or oblique in 7 studies (6.0%), and not reported in 80 studies (68.4%). Antibiotic prophylaxis was given as standard in 45 studies (38.5%), not standardised in 13 studies (11.1%), and not reported in 59 studies (50.4%). Skin preparation was standardised in 21 studies (18.0%), not standardised in 4 studies (3.4%), and not reported in 92 studies (78.6%). Of studies where skin preparation was standardised, 6 used an iodine-based solution, 6 used a chlorhexidine-based solution, 1 used denatured ethanol, 1 used hexachlorophene, 1 used Kodan Tinkfur Forte, 1 study standardised the solution but did not report the name, and 3 studies allowed a choice between an iodinebased solution and chlorhexidine-based solution. There was no reporting of details regarding pre-operative bathing/showering in 106 (90.6%) and pre-operative shaving in 99 (84.6%).

The incidence of seroma, haematoma, lymphatic leak, and re-intervention to manage SSI were infrequently reported. The overall incidence of each were 5.7% (157/2734), 2.5% (171/6696), 4.5% (298/6589) and 2.5% (205/8373) per incision respectively.

## 4 | DISCUSSION

This systematic review identified 117 studies that reported an overall groin wound SSI incidence of 8.1% after arterial intervention. SSIs were more frequently superficial (6.3%) than deep (1.9%). Studies only including patients undergoing procedures for aneurysmal pathology reported a lower SSI incidence when compared with studies only including patients with occlusive pathology and with studies including patients with aneurysmal or occlusive pathology. This was consistent when examining RCTs and observational subgroups separately. The control arms of RCTs were consistently reported as experiencing more SSIs when compared with the intervention arms of RCTs. Aneurysmal pathology (in relation to occlusive) and retrospective observational study design (in relation to RCT) were identified as predictors of a lower reported SSI incidence. SSI being a primary outcome was identified as a predictor of a higher reported SSI incidence.

This review highlights that clinicians should be aware of study-level factors that influence the reported incidence of SSIs. Those wishing to benchmark their own practice should identify studies where the pathology being treated most closely aligns with their practice and include SSI as a primary outcome. Clinicians whose surveillance of SSIs does not include community/primary care surveillance should be aware that the pooled incidence from observational studies is the figure most likely to be representative of their observed incidence, and therefore likely to be approximately 8.0%. These SSIs may well be those which become apparent to the vascular surgeon<sup>22,23</sup>; however, it appears many superficial SSIs are missed by observational studies, despite being a potential source of morbidity and increased health care costs.<sup>24</sup> Studies on SSIs following general surgical procedures report that approximately half of all SSIs are diagnosed in the community and that many were managed completely by primary care.<sup>24,25</sup> Further observational studies with robust follow-up data capture are needed to quantify post-discharge vascular groin wound SSI and the impact on patients and health care costs. Other methods of community surveillance such as wound guestionnaires are an attractive, resource-efficient concept that show promising accuracy and reliability but require validation in a vascular surgery specific cohort.<sup>26</sup>

Results concerning the control arms of the RCTs will be valuable to researchers aiming to evaluate groin wound SSI preventing interventions/strategies. These results can be used to inform power calculations when designing future trials. Insight into the superficial and deep SSI incidences identified in this review could inform the design of trials that evaluate more expensive prophylactic interventions, the cost-efficiency of which are not yet determined<sup>9</sup>; it may be appropriate to use these selectively in patients most at risk of deep SSIs. However, predicting vascular groin wound SSIs reliably is challenging,<sup>27</sup> with few, if any, robust risk prediction tools in this cohort. Most of the included RCTs evaluate

## 

an intervention aimed at preventing groin wound SSIs and most have been included in previous reviews and subjected to meta-analyses.<sup>9,28</sup> Most of the RCTs evaluating prophylactic antibiotics were published over 20 years ago and were heterogenous in design. Several evaluate regimes that continues for at least 24 h postoperatively but, crucially, none compare extended regimes with what would be considered standard practice (one-off dose pre-operatively/on induction). A recent RCT demonstrated that an extended course of antibiotic prophylaxis reduced SSIs following minor and major amputation, it is currently unknown whether a similar intervention would be efficacious in preventing groin wound SSIs.<sup>29</sup>

There were differences in the incidences of SSIs between studies using different SSI definitions. Univariate analyses demonstrated that when compared with studies not reporting how SSI was defined; studies using the CDC criteria reported a lower SSI incidence and studies using the Szilagyi classification reported a higher SSI incidence. Differences in results based on differing SSI definitions have been demonstrated before.<sup>30</sup> This could have resulted from the key differences between the two: the Szilagyi description is less detailed and more likely to introduce subjectivity, and the CDC criteria exclude certain complications (eg, stitch abscess). However, multivariate meta-regression results did not find that this variable remained significant.

Observational studies reported lower incidences of SSIs compared with RCTs, with the exception of when SSI was not a primary outcome. This finding is likely to be heavily influenced by differences in follow-up data capture between study types. Observational studies are more likely to rely on medical records as source data as opposed to dedicated follow-up patient review or interview, either because of design choice in prospective studies,<sup>31</sup> or necessity in the case of retrospective registry studies.<sup>2</sup> Both administrative and clinical registry data are known to have inaccuracies.<sup>32</sup> In addition, milder SSIs which commonly occur post-discharge,<sup>24</sup> especially given that some definitions include infections up to 90 days postoperatively,<sup>19</sup> are potentially identified and treated entirely in primary care.<sup>24</sup> This compounds data inaccuracy especially in single health care systems or organisations that have a disconnect between their own primary and secondary care data.<sup>33-35</sup> The difference in ratio of superficial to deep SSIs between observational studies and RCTs identified in this review highlight that it is the superficial SSIs (rather than deep SSIs) which are underreported by observational studies.

SSI being a primary outcome was an independent predictor of a higher incidence of SSIs. This is likely the result of study design ensuring robust data collection and accuracy of the primary outcome.<sup>36</sup> If SSI was not a primary outcome in RCTs the ratio of superficial to deep infections suggest that the 'missed cases' were mostly superficial. Deep infections are more likely to require hospitalisation and operative re-intervention,<sup>23,37</sup> and are therefore, more readily apparent to the treating (and study) team. The finding that reported SSI rates in RCTs are higher if SSI is a primary outcome (compared with a secondary outcome) is congruent with findings from a review of RCT data on SSIs following gastrointestinal surgery.<sup>38</sup>

It was not surprising that studies only including patients with aneurysmal pathology reported a lower incidence of SSIs compared with studies only including patients with occlusive pathology or a mix of patients with aneurysmal and occlusive pathology. A lower incidence can likely be attributed, in part, to studies that include cut-downs for endovascular aneurysm repair, in which SSIs are infrequent. In addition, peripheral arterial disease itself and factors that commonly accompany the disease (relative to aneurysmal pathology) such as diabetes mellitus, obesity and presence of peripheral wounds (with/without active infection) are well recognised risk factors for SSI.<sup>12,39,40</sup>

A limitation of this review is that several patient-level variables could not be captured in detail, which prevents a more detailed description of how study population can influence the observed SSI incidence, and a more robust meta-regression. Most groin incisions included in this review were from observational studies, therefore, the overall calculated SSI incidences are heavily weighted by studies that are incompletely capturing SSIs; the true incidence of groin wound SSI after arterial intervention is likely higher and closer to that of our reported RCT incidence. There was inconsistent reporting of SSI incidence as 'per incision', some studies only reported the incidence on a 'per patient' basis; therefore, this result could not be calculated using data from all studies. The regression analyses were limited to a relatively low number of predictor variables because of the relatively low number of 'cases' (studies), there are other potentially relevant study-level variables such as geographical location and funding source that could not be explored for this reason.

## 5 | CONCLUSION

The overall incidence of groin wound SSI after arterial intervention reported in the literature is 8.1% (6.3% superficial and 1.9% deep). Studies that only include patients with aneurysmal pathology (relative to occlusive) and retrospective observational study design (relative to RCT) was associated with a lower reported incidence of SSIs. SSI being a primary outcome was associated with a higher reported incidence of SSIs. Our results concerning RCT data could be used to inform trial

design, whilst results concerning observational studies suggest that a significant proportion of superficial SSIs occur in the community and are missed by many observational studies and vascular teams.

## **CONFLICT OF INTEREST**

The authors declare no potential conflict of interest.

## DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

## ORCID

Brenig Llwyd Gwilym D https://orcid.org/0000-0002-5403-8720

David Charles Bosanquet Dhttps://orcid.org/0000-0003-2304-0489

## REFERENCES

- van de Weijer MAJ, Kruse RR, Schamp K, Zeebregts CJ, Reijnen MMPJ. Morbidity of femoropopliteal bypass surgery. *Semin Vasc Surg.* 2015;28(2):112-121. doi:10.1053/j.semvas csurg.2015.09.004
- Wiseman JT, Fernandes-Taylor S, Barnes ML, et al. Predictors of surgical site infection after hospital discharge in patients undergoing major vascular surgery. *J Vasc Surg.* 2015;62:1023-1031.e5. doi:10.1016/j.jvs.2015.04.453
- Voegeli D. Intertrigo: causes, prevention and management. Br J Nurs. 2020;29(12):S16-S22. doi:10.12968/BJON.2020.29. 12.S16
- WHO. Global guidelines for the prevention of surgical site infection. https://apps.who.int/iris/bitstream/handle/10665/250680/ 9789241549882-eng.pdf?sequence=8. Accessed July 1, 2021.
- Smith AD, Hawkins AT, Schaumeier MJ, De Vos MS, Conte MS, Nguyen LL. Predictors of major amputation despite patent bypass grafts. *J Vasc Surg.* 2016;63:1279-1288.
- Siracuse JJ, Nandivada P, Giles KA, et al. Prosthetic graft infections involving the femoral artery. *J Vasc Surg.* 2013;57(3):700-705. doi:10.1016/j.jvs.2012.09.049
- Chakfé N, Diener H, Lejay A, et al. 2020 Clinical Practice Guidelines on the management of vascular graft and stent graft infections with the endorsement of the European Association of Nuclear Medicine (EANM). *Eur J Vasc Endovasc Surg.* 2020; 59(3):339-384. doi:10.1016/j.ejvs.2019.10.016
- Smith GE, Long J, Wallace T, Carradice D, Chetter IC, Collaborative VR. Identifying the research priorities of healthcare professionals in UK vascular surgery: modified Delphi approach. *BJS Open*. 2021;5(2):zraa025. doi:10.1093/ BJSOPEN/ZRAA025
- Gwilym BL, Bosanquet DC, Dovell G, et al. Systematic review and meta-analysis of wound adjuncts for the prevention of groin wound surgical site infection in arterial surgery. *Eur J Vasc Endovasc Surg.* 2021;61(4):636-646. doi:10.1016/j.ejvs.2020.11.053
- Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *Eur J Vasc Endovasc Surg.* 2019;58(1):S1-S109.e33. doi:10. 1016/J.EJVS.2019.05.006

- Wanhainen A, Verzini F, Van Herzeele I, et al. European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. *Eur J Vasc Endovasc Surg.* 2019;57(1):8-93. doi:10. 1016/J.EJVS.2018.09.020
- Groin wound Infection after Vascular Exposure (GIVE) Study Group. Groin wound infection after vascular exposure (GIVE) multicentre cohort study. *Int Wound J.* 2021;18(2):164-175. doi: 10.1111/iwj.13508
- Kuy S, Dua A, Desai S, et al. Surgical site infections after lower extremity revascularization procedures involving groin incisions. *Ann Vasc Surg.* 2014;28:53-58.
- Trinidad B, Rybin D, Doros G, Eslami M, Tan TW. Factors associated with wound complications after open femoral artery exposure for elective endovascular abdominal aortic aneurysm repair. *Int J Angiol.* 2019;28(2):124-129. doi:10.1055/s-0039-1683898
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6:e1000097. doi:10.1371/journal.pmed. 1000097
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:14898. doi:10.1136/BMJ.L4898
- Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/ programs/clinical\_epidemiology/oxford.htm. Accessed July 1, 2021.
- Szilagyi DE, Smith RF, Elliot JP, Vrandecic MP. Infection in arterial reconstruction with synthetic grafts. *Ann Surg.* 1972; 176(3):321-333. doi:10.1097/00000658-197209000-00008
- Centers for Disease Control and Prevention National Healthcare Safety Network. Surgical site infection event (SSI). https:// www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf. Accessed July 1, 2021.
- Bailey IS, Karran SE, Toyn K, Brough P, Ranaboldo C, Karran SJ. Community surveillance of complications after hernia surgery. *BMJ*. 1992;304(6825):469-471. doi:10.1136/bmj.304. 6825.469
- Wilson APR, Sturridge MF, Treasure T, Grüneberg RN. A scoring method (asepsis) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. *Lancet.* 1986;327(8476):311-312. doi:10.1016/S0140-6736(86) 90838-X
- Bennett KM, Levinson H, Scarborough JE, Shortell CK. Validated prediction model for severe groin wound infection after lower extremity revascularization procedures. *J Vasc Surg.* 2016;63(2):414-419. doi:10.1016/j.jvs.2015.08.094
- Dosluoglu HH, Loghmanee C, Lall P, Cherr GS, Harris LM, Dryjski ML. Management of early (<30 day) vascular groin infections using vacuum-assisted closure alone without muscle flap coverage in a consecutive patient series. *J Vasc Surg.* 2010; 51(5):1160-1166. doi:10.1016/J.JVS.2009.11.053
- Sullivan E, Gupta A, Cook CH. Cost and consequences of surgical site infections: a call to arms. *Surg Infect*. 2017;18(4):451-454. doi:10.1089/SUR.2017.072
- 25. Reeves N, Cuff S, Boyce K, et al. Diagnosis of colorectal and emergency surgical site infections in the era of enhanced

recovery: an all-Wales prospective study. *Colorectal Dis.* 2021; 23(5):1239-1247. doi:10.1111/CODI.15569

- Bluebelle Study Group. Validation of the Bluebelle wound healing questionnaire for assessment of surgical-site infection in closed primary wounds after hospital discharge. *BJS*. 2019; 106(3):226-235. doi:10.1002/bjs.11008
- 27. Gwilym BL, Ambler GK, Saratzis A, Bosanquet DC, Groin wound Infection after Vascular Exposure (GIVE) Study Group. Groin wound infection after vascular exposure (GIVE) risk prediction models—development, internal validation, and comparison to existing risk prediction models identified in a systematic review of the literature. *Eur J Vasc Endovasc Surg.* 2021;62(2):258-266. doi:10.1016/j.ejvs. 2021.05.009
- Gombert A, Dillavou E, D'Agostino R, Griffin L, Robertson JM, Eells A. A systematic review and meta-analysis of randomized controlled trials for the reduction of surgical site infection in closed incision management versus standard of care dressings over closed vascular groin incisions. *Vascular*. 2020;28(3):274-284. doi:10.1177/1708538119890960
- Souroullas P, Barnes R, Carradice D, Smith G, Huang C, Chetter I. Extended-course antibiotic prophylaxis in lower limb amputation: randomized clinical trial. *Br J Surg.* 2022;109(5): 426-432. doi:10.1093/BJS/ZNAC053
- Audu CO, Columbo JA, Sun SJ, et al. Variation in timing and type of groin wound complications highlights the need for uniform reporting standards. *J Vasc Surg.* 2019;69(2):532-543. doi: 10.1016/j.jvs.2018.05.221
- Gwilym BL, Saratzis A, Benson R, et al. Study protocol for the groin wound infection after vascular exposure (GIVE) audit and multicentre cohort study. *Int J Surg Protoc.* 2019;16:9-13. doi:10.1016/j.isjp.2019.06.001
- Burns EM, Rigby E, Mamidanna R, et al. Systematic review of discharge coding accuracy. *J Public Health*. 2012;34(1):138-148. doi:10.1093/PUBMED/FDR054
- Bradley SH, Lawrence NR, Carder P. Using primary care data for health research in England—an overview. *Future Healthc J.* 2018;5(3):207-212. doi:10.7861/FUTUREHOSP.5-3-207
- Godlee F. What can we salvage from care.data? *BMJ*. 2016;354: i3907. doi:10.1136/BMJ.I3907
- Van Staa TP, Goldacre B, Buchan I, Smeeth L. Big health data: the need to earn public trust. *BMJ*. 2016;354:i3636. doi:10.1136/ BMJ.I3636
- Andrade C. The primary outcome measure and its importance in clinical trials. J Clin Psychiatry. 2015;76(10):15598. doi:10. 4088/JCP.15F10377
- Newington DP, Houghton PWJ, Baird RN, Horrocks M. Groin wound infection after arterial surgery. *Br J Surg.* 1991;78(5): 617-619. doi:10.1002/bjs.1800780530
- Matthews JH, Bhanderi S, Chapman SJ, Nepogodiev D, Pinkney T, Bhangu A. Underreporting of secondary endpoints in randomized trials: cross-sectional, observational study. *Ann Surg.* 2016;264(6):982-986. doi:10.1097/SLA.000 0000000001573
- STARSurg Collaborative. Multicentre prospective cohort study of body mass index and postoperative complications following gastrointestinal surgery. *Br J Surg.* 2016;103(9):1157-1172. doi: 10.1002/bjs.10203

 Inui T, Bandyk DF. Vascular surgical site infection: risk factors and preventive measures. *Semin Vasc Surg.* 2015;28(3–4):201-207. doi:10.1053/j.semvascsurg.2016.02.002

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article. **How to cite this article:** Gwilym BL, Locker DT, Matthews EK, et al. Systematic review of groin wound surgical site infection incidence after arterial intervention. *Int Wound J.* 2022;1-16. doi:10.1111/iwj.13959